Clinical Trial

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Study acronym: SURPASS-T1D-1
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2025-04-04; most recent amendment 2026-05-11.
Status change: Recruiting → Active, Not Recruiting 2026-02-13
Status change: Not Yet Recruiting → Recruiting 2025-04-25
Trial Details
NCT Number NCT06914895
Lead Sponsor Eli Lilly and Company
Conditions Type 1 Diabetes, Obesity, Overweight
Enrollment 905 participants
Start Date 2025-04-25
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-12